Efficacy and tolerability of once‐weekly selinexor, bortezomib, and dexamethasone in comparison with standard twice‐weekly bortezomib and dexamethasone in previously treated multiple myeloma with renal impairment: Subgroup analysis from the BOSTON study

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	American journal of hematology 2022-03, Vol.97 (3), p.E83-E86
Hauptverfasser:	Delimpasi, Sosana, Mateos, Maria Victoria, Auner, Holger W., Gavriatopoulou, Maria, Dimopoulos, Meletios A., Quach, Hang, Pylypenko, Halyna, Hájek, Roman, Leleu, Xavier, Dolai, Tuphan Kanti, Sinha, Dinesh Kumar, Venner, Christopher P., Benjamin, Reuben, Garg, Mamta Krishnan, Doronin, Vadim, Levy, Yair, Moreau, Philippe, Chai, Yi, Arazy, Melina, Shah, Jatin, Shacham, Sharon, Kauffman, Michael G., Richardson, Paul G., Grosicki, Sebastian
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Combined Chemotherapy Protocols - administration & dosage Bortezomib Bortezomib - administration & dosage Dexamethasone Dexamethasone - administration & dosage Disease-Free Survival Female Hematology Humans Hydrazines - administration & dosage Inhibitor drugs Kidney Diseases - drug therapy Kidney Diseases - mortality Male Middle Aged Multiple myeloma Multiple Myeloma - drug therapy Multiple Myeloma - mortality Steroids Survival Rate Targeted cancer therapy Triazoles - administration & dosage
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!